



Lactobacillus Mucosal Vaccine Vectors: Immune Responses against Bacterial and Viral Antigens

 Jonathan S. LeCureux,^a  Gregg A. Dean^b

^aDepartment of Natural and Applied Sciences, Evangel University, Springfield, Missouri, USA

^bDepartment of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA

ABSTRACT Lactic acid bacteria (LAB) have been utilized since the 1990s for therapeutic heterologous gene expression. The ability of LAB to elicit an immune response against expressed foreign antigens has led to their exploration as potential mucosal vaccine candidates. LAB vaccine vectors offer many attractive advantages: simple, noninvasive administration (usually oral or intranasal), the acceptance and stability of genetic modifications, relatively low cost, and the highest level of safety possible. Experimentation using LAB of the genus *Lactobacillus* has become popular in recent years due to their ability to elicit strong systemic and mucosal immune responses. This article reviews *Lactobacillus* vaccine constructs, including *Lactobacillus* species, antigen expression, model organisms, and *in vivo* immune responses, with a primary focus on viral and bacterial antigens.

KEYWORDS *Lactobacillus*, mucosal immunity, mucosal vaccines

Lactic acid bacteria (LAB), alongside other food-based platforms, have been utilized since the 1990s for therapeutic heterologous gene expression (1). The ability of LAB to elicit an immune response against expressed foreign antigens has led to their use as potential candidates as mucosal vaccine vectors. As vaccine vectors, they offer several attractive advantages: simple, noninvasive administration (usually oral or intranasal), the acceptance and maintenance of genetic modifications, low cost, and high safety levels. LAB tend to elicit minimal immune responses against themselves, instead inducing high levels of systemic and mucosal antibodies against the expressed foreign antigen following uptake via the mucosal immune system (2).

LAB for use as vaccine vectors generally include *Streptococcus gordonii*, *Lactococcus lactis*, or multiple *Lactobacillus* species. *S. gordonii* has generally fallen out of use, with a few exceptions (3). *L. lactis* and *Lactobacillus* spp. have continued to grow in use, with the number of publications continuing to increase. Several excellent reviews of *L. lactis* vaccines have been published (4–6), as well as articles describing how to generate these recombinant bacteria (7). Because of the large number of recent articles detailing lactobacilli as vaccine vectors, this review focuses on those publications and on the resulting immune responses generated *in vivo*.

Briefly, this review is divided into sections corresponding to the pathogen/disease of interest (virus, bacterium). Pathogen species or families that have been investigated in multiple studies (i.e., human immunodeficiency virus [HIV], *Escherichia coli*) are then highlighted, focusing on the immune responses resulting from *Lactobacillus* vaccination. This review covers only research involving *Lactobacillus* strains with heterologous gene expression. Studies conducted with unmodified *Lactobacillus* used either as an adjuvant or for intrinsic antibacterial or antiviral properties are excluded (8, 9). The text of this review focuses on *in vivo* immune responses and on selected *in vitro* studies with

Published 16 May 2018

Citation LeCureux JS, Dean GA. 2018.

Lactobacillus mucosal vaccine vectors: immune responses against bacterial and viral antigens. mSphere 3:e00061-18. <https://doi.org/10.1128/mSphere.00061-18>.

Editor Christopher J. Papanian, UMKC School of Medicine

Copyright © 2018 LeCureux and Dean. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Gregg A. Dean, Gregg.dean@colostate.edu.

a significant immune component, with Table 1 highlighting viral antigens and Table 2 highlighting bacterial antigens.

VIRUSES

Human immunodeficiency virus. Human immunodeficiency virus type 1 (HIV-1) has been relegated to the status of being a treatable chronic disease, and yet infection rates are unacceptably high (10). An effective HIV vaccine is still elusive via traditional methods, with statistical significance limitations plaguing the only modestly successful clinical trial (11). Utilizing lactobacilli as mucosal vaccine vectors can provide an enhanced immune response at the typical mucosal sites of infection. Several studies have looked at lactobacilli expressing HIV antigens, thus targeting the virus at the most common site of infection, namely, the mucosa. Our laboratory has shown that expressing additional secreted molecules as adjuvants (interleukin 1 β [IL-1 β], *Salmonella* flagellin C) can significantly improve the mucosal (IgA) and systemic (serum IgG) immune responses against HIV proteins (MPER, Gag) in orally dosed mice (12, 13). Kuczkowska et al. have shown *in vitro* evidence of T cell recruitment using an *L. plantarum* strain expressing a fusion protein of CCL3/HIV Gag (14). No challenge studies in monkeys or humans have been performed to determine the efficacy of the immune response.

An alternative preventative measure against HIV is the use of prophylactic topical microbicides, which can be effective in high-risk groups (15). By incorporating microbicide expression into lactobacilli, mucosal sites can be colonized and continuously protected, reducing cost and the need for strict adherence. In two separate studies, Lagenaur et al. utilized a vagina-associated *L. jensenii* strain secreting cyanovirin-N, a promising microbicide with high affinity for HIV envelope glycoproteins. This application was safe in rhesus macaques and afforded protection against simian-human immunodeficiency virus (SHIV) challenge (16–18). That group also used lactobacilli for secretion of broadly neutralizing antibody fragments to protect the vaginal mucosa, though the work was still performed *in vitro* (19). Human trials are under way.

Human papillomavirus. The association between human papillomavirus (HPV) and various cancers, particularly cervical cancer, is well known (20). Because of this association, HPV proteins are usually expressed on the surface cervical cancer cells. This allows an immune response that not only targets potentially infectious virus but can also destroy infected, cancerous cells. There are currently two FDA-approved vaccines against the most common strains of HPV (vaccines Gardasil and Cervarix). Both generate protective immune responses via spontaneous virus-like particle (VLP) formation of the HPV L1 capsid protein (21). While these vaccines provide excellent protection and represent potential cancer therapies, the cost can prove prohibitive even in the United States (22). Only one research group has utilized *Lactobacillus* to generate VLPs using the L1 protein, resulting in serum IgG expression following subcutaneous injection in BALB/c mice (23). All other research groups have utilized surface expression of HPV proteins, either minor capsid protein L2 or the early oncoproteins E6 and E7, which are directly responsible for unregulated cellular replication (24). In an extensive set of early experiments, Poo et al. utilized an E7-expressing *L. casei* strain, observing serum IgG along with intestinal and vaginal IgA in orally immunized C57BL/6 mice. They also observed E7-specific gamma interferon (IFN- γ)-secreting cells in the vagina and spleen, as well as a therapeutic reduction in tumor size and increased animal survival following TC-1 tumor cell challenge (25). A similar study using E6 had similar results (26). Poo et al. later targeted the L2 protein in BALB/c mice, observing serum IgG, mucosal IgG and IgA, and cross-neutralization with related viruses (27). Using *L. casei* administered to C57BL/6, Adachi et al. observed increased levels of E7-specific T cells in the gut, as well as granzyme-B production. Mucosal lymphocytes were found to be capable of TC-1 cell lysis, a result which was also repeated by another research group (28, 29). Interestingly, oral administration improved the response in comparison to the results seen with subcutaneous or intramuscular administration (28). Another research group utilized *L. plantarum* expressing E7, with similar antibody and antitumor results, though they

TABLE 1 Primary articles describing studies that utilized *Lactobacillus* to express viral antigens^a

Pathogen	<i>Lactobacillus</i> species	Antigen(s) expressed	Expression	Result(s)	Intended host(s)	Reference
CAV	<i>L. acidophilus</i>	VP1	Surface	Serum Ab, T cell response	Poultry	93
CSFV	<i>L. plantarum</i>	E2	Surface	Serum IgG, mucosal IgA, T cell response	Swine	62
CSFV	<i>L. casei</i>	CTL 290	Secreted	Serum IgG, mucosal IgA, T cell response, challenge	Swine	60
CSFV	<i>L. casei</i>	CTL 290	Unknown	Serum IgG, T cell response, challenge	Swine	61
CSFV	<i>L. casei</i>	CTL 290	Secreted	Serum IgG, mucosal IgA	Swine	94
CyHV-3	<i>L. plantarum</i>	ORF81	Surface	IgM, challenge	Fish	59
FMDV	<i>L. casei, L. plantarum</i>	VP1	Intracellular	Serum Ab, mucosal IgA	Human	95
FMDV	<i>L. acidophilus</i>	VP1	Unknown	Serum IgG, T cell response	Animal	66
GPV	<i>L. plantarum</i>	VP2	Unknown	Mucosal sIgA, TNF- α , IFN- γ , T cell response	Poultry	96
HDV	<i>L. casei, L. plantarum</i>	HDVag	Intracellular	Serum Ab, mucosal IgA	Human	95
HIV	<i>L. jensenii</i>	scFv m9, dAb m36, m36.4	Secreted	Stability	Human	19
HIV	<i>L. acidophilus</i>	MPER	Surface	Serum IgG, mucosal IgA, mucosal IgG	Human	13
HIV	<i>L. plantarum</i>	Gag	Surface	<i>In vitro</i> T cell line chemotaxis	Human	14
HIV	<i>L. jensenii</i>	CV-N	Secreted	Safety, toxicity	Human	17
HIV	<i>L. acidophilus</i>	Gag	Surface	Mucosal IgA	Human	12
HIV	<i>L. jensenii</i>	CV-N	Secreted	Challenge	Human	16
HIV	<i>L. fermentum</i>	Gp41	Surface	Stability	Human	97
HIV	<i>L. jensenii</i>	CV-N	Secreted	Safety, toxicity	Human	18
HPV	<i>L. casei</i>	E7	Unknown	T cell response	Human	98
HPV	<i>L. casei</i>	L2	Surface	Serum IgG, mucosal IgG, mucosal IgA, challenge	Human	27
HPV	<i>L. casei</i>	E7	Surface	CTL response, challenge	Human	29
HPV	<i>L. casei</i>	E6	Surface	Serum IgG, mucosal IgA, challenge, cross-neutralization	Human	26
HPV	<i>L. plantarum</i>	E7	Surface	Serum IgG, challenge	Human	30
HPV	<i>L. casei</i>	E7	Surface	Serum IgG, mucosal IgA, challenge	Human	25
HPV	<i>L. casei</i>	E7	Surface	T cell response	Human	28
HPV	Unknown	E7	Surface	Unknown	Human	99
HPV	<i>L. casei</i>	L1, VLP	Intracellular	Serum IgG	Human	23
HPV	<i>L. plantarum</i>	E7	Surface	Stability	Human	100
HPV	<i>L. casei</i>	E7	Unknown	Increased cervical lymphocytes, decreased pathology	Human	31
IBDV	<i>L. casei</i>	VP2	Unknown	Serum IgG, mucosal IgA, challenge survival	Poultry	101
IBV	<i>L. salivarius</i>	EpiC	Surface	Stability, toxicity	Poultry	102
IBV	<i>L. salivarius</i>	EpiC	Secreted	Stability	Poultry	102
Influenza virus	<i>L. casei</i>	NP	Unknown	Stability	Human	103
Influenza virus	<i>L. casei</i>	sM2, HA2	Surface	Serum IgG, mucosal IgA, challenge	Human, animal	37
Influenza virus	<i>L. casei</i>	sM2	Surface	Serum IgG, mucosal IgA, T cell response, challenge	Human	36
Influenza virus	<i>L. delbrueckii</i>	HA	Unknown	Serum IgG, mucosal IgA, challenge	Poultry	35
Influenza virus	<i>L. casei</i>	NP	Unknown	Stability	Human	104
Influenza virus (H1N1)	<i>L. plantarum</i>	M2e	Unknown	Mucosal IgA, T cell response, challenge	Human, swine	105
Influenza virus (H5N1)	<i>L. acidophilus, L. delbrueckii</i>	HA	Unknown	Serum IgG, mucosal IgA	Human, poultry	34
Influenza virus (H9N2)	<i>L. plantarum</i>	HA	Unknown	Serum IgG, mucosal IgA, T cell response, challenge	Poultry	33
Influenza virus (H9N2)	<i>L. plantarum</i>	NP, M1	Unknown	Serum IgG, mucosal sIgA, T cell response, challenge	Poultry	106
Influenza virus (H9N2)	<i>L. plantarum</i>	HA	Unknown	Serum IgG, mucosal IgA, T cell response, challenge	Poultry	32
Influenza virus (H9N2)	<i>L. plantarum</i>	NP, M1	Unknown	Mucosal IgA, T cell response, challenge	Poultry	107
Influenza virus (H5N1)	<i>L. casei</i>	NS1	Surface	Stability	Human, Poultry	108
IPNV	<i>L. casei</i>	VP2, VP3	Surface, secreted	Serum IgM, challenge protection	Fish	58
IPNV	<i>L. casei</i>	VP2	Surface, secreted	Serum IgM, challenge	Fish	57
NDV	<i>L. plantarum</i>	HN	Unknown	Serum IgA, mucosal IgA, T cell response, challenge	Poultry	65
Norwalk virus	<i>L. casei</i>	VP60	Intracellular	Stability	Human	109

(Continued on next page)

TABLE 1 (Continued)

Pathogen	<i>Lactobacillus</i> species	Antigen(s) expressed	Expression	Result(s)	Intended host(s)	Reference
PEDV	<i>L. casei</i>	COE	Surface	Serum IgG, mucosal IgA, T cell response, > neutralization	Swine	45
PEDV	<i>L. casei</i>	S1, N	Surface, secreted	Serum IgG, mucosal IgA	Swine	44
PEDV	<i>L. casei</i>	N	Surface	Serum IgG, mucosal IgA	Swine	110
PEDV	<i>L. casei</i>	N	Surface	Serum IgG, mucosal IgA	Swine	46
Porcine RV	<i>L. casei</i>	VP4	Surface	Serum IgG, mucosal IgA, neutralization	Swine	53
Porcine RV	<i>L. acidophilus</i>	VP7	Unknown	Mucosal IgA, challenge	Swine	111
Porcine RV	<i>L. casei</i>	VP4	Unknown	Serum IgG, mucosal sIgA, neut. Ab	Swine	112
PPV	<i>L. casei</i>	VP2	Secreted	Serum IgG, mucosal IgA, T cell response, challenge	Swine	60
PPV	<i>L. casei</i>	VP2	Surface, secreted	Serum IgG, mucosal IgA	Swine	64
PPV	<i>L. casei</i>	VP2	Secreted	Serum IgG, mucosal IgA	Swine	94
PPV	<i>L. casei</i>	VP2	Surface	Serum IgG, mucosal IgA	Swine	63
RV	<i>L. rhamnosus</i>	ARP1	Surface	Challenge	Human	54
RV	<i>L. paracasei</i>	ARP1–ARP3	Surface, secreted	Stability	Human	113
RV	<i>L. rhamnosus</i>	IgGb, IgGd	Surface	Challenge	Human	55
SARS-CoV	<i>L. casei</i>	SA, SB	Surface	Serum IgG, mucosal IgA	Human	42
SVCV	<i>L. plantarum</i>	GP	Surface	IgM, challenge	Fish	59
TGEV	<i>L. casei</i>	D	Surface	Serum IgG, mucosal IgA, T cell response, challenge	Swine	47
TGEV	<i>L. casei</i>	MDP	Surface	Serum IgG, mucosal IgA, T cell response, neutralization	Swine	41
TGEV	<i>L. pentosus</i>	6D	Surface, secreted	Serum IgG, mucosal IgA	Swine	40
TGEV	<i>L. casei</i>	S	Secreted	Serum IgG, mucosal IgA	Swine	39

^aCAV, chicken anemia virus; CyHV-3, cyprinid herpesvirus 3; FMDV, foot-and-mouth disease virus; GPV, goose parvovirus; HDV, hepatitis D virus; IBDV, infectious bursal disease virus; IBV, infectious bronchitis virus; NDV, Newcastle disease virus; Porcine RV, porcine rotavirus; PPV, porcine parvovirus; SVCV, spring viremia of carp virus; Ab, antibody; neut. Ab, neutralizing antibody; sIgA, secretory immunoglobulin G; scFv, single chain variable fragment.

checked only for antibodies in the serum and not in the mucosa (30). Because of the observed therapeutic effect seen in several studies, a human trial using cervical cancer (cervical intraepithelial neoplasia grade 3 [CIN3]) patients was conducted and demonstrated the presence of E7-specific lymphocytes in cervical tissues but not in blood, with the majority of patient tumor pathologies being downgraded (31). Taken together, the data show great promise and potential for the development of anti-HPV *Lactobacillus* vaccines to meet an important public health need.

Influenza virus. The unpredictability of the availability of future influenza virus strains, as well as supply problems stemming from slow growth methods (egg and cell based), means that anti-influenza *Lactobacillus* vaccines could fill a need, particularly for treatment of infections by highly pathogenic strains such as H5N1. Shi et al. showed that oral administration of an *L. plantarum* strain expressing H9N2 hemagglutinin (HA) induced fecal IgA, bronchiolar IgA, and serum IgG. B cell levels in secondary lymphoid organs were increased, and CD8⁺ T cell proliferation and IFN- γ secretion were greatly improved relative to the levels seen with a typical influenza vaccine. Most importantly, vaccinated mice survived lethal challenge (32). These results were seen again in assays using dendritic cell-targeting peptide (DC-pep) adjuvant, which showed improved immune responses and challenge survival in chickens (33). Similar antibody and T cell results were observed in targeting H5N1 hemagglutinin (HA₁) in BALB/c mice (34) and chickens (35). Other influenza virus proteins have also been targeted. Chowdhury et al. granted BALB/c mice protection (via oral or intranasal administration) from multiple lethal challenge strains and showed that inclusion of cholera toxin subunit A1 (CTA1) significantly improved antibody levels and protection (36). A follow-up study showed that antibody levels and IFN- γ secretion and proliferation, as well as protection against lethal challenge, lasted 7 months postvaccination (37).

Coronavirus. Until the recent outbreaks of severe acute respiratory syndrome (SARS) (2003) and Middle East respiratory syndrome (MERS) (2014/2015), coronavirus (CoV) morbidity and mortality were generally worse for domesticated animals rather than for humans, particularly within porcine and poultry farms. Coronaviruses usually

TABLE 2 Primary articles describing studies that utilized *Lactobacillus* to express bacterial antigens^a

Pathogen	<i>Lactobacillus</i> species	Antigen(s) expressed	Expression	Result(s)	Intended host(s)	Reference
<i>Bacillus anthracis</i>	<i>L. gasseri</i>	PA	Unknown	Serum IgG, mucosal IgA, T cell response	Human, animal	71
<i>Bacillus anthracis</i>	<i>L. gasseri</i>	PA	Unknown	Neutr. Ab, T cell response, challenge	Human	70
<i>Bacillus anthracis</i>	<i>L. acidophilus</i>	PA	Surface	Neutr. Ab, mucosal IgA, challenge	Human	69
<i>Bacillus anthracis</i>	<i>L. casei</i>	PA	Surface, intracell., secreted	Serum IgG	Human	68
<i>Bacillus anthracis</i>	<i>L. acidophilus</i>	PA	Surface	Stability	Human	114
<i>Borrelia burgdorferi</i>	<i>L. plantarum</i>	OspA	Surface	Serum IgG, mucosal IgA	Human	83
<i>Borrelia burgdorferi</i>	<i>L. plantarum</i>	OspA	Unknown	Serum IgG, mucosal IgA, challenge	Human	82
<i>Bordetella pertussis</i>	<i>L. casei</i>	FHA	Intracell.	Serum IgG	Human	115
<i>Clostridium botulinum</i>	<i>L. acidophilus</i>	BoNT/A-Hc	Surface	Stability	Human	114
<i>Clostridium perfringens</i>	<i>L. casei</i>	ϵ -Toxoid	Surface	Serum IgG, serum IgA, intestinal IgA, IFN- γ , challenge	Human, animal	86
<i>Clostridium perfringens</i>	<i>L. casei</i>	α -, β 1-, β 2-, ϵ -toxoids	Unknown	Serum IgG, fecal IgA, nasal IgA, IFN- γ /IL-4, T cell response, challenge	Human, animal	116
<i>Clostridium perfringens</i>	<i>L. casei</i>	β -Toxoid	Surface, intracell.	Serum IgG, serum IgA, intestinal IgA, IFN- γ , challenge	Human, animal	117
<i>Clostridium perfringens</i>	<i>L. casei</i>	α -Toxoid	Surface	Serum IgG, mucosal IgA, challenge	Human, animal	118
<i>Chlamydia psittaci</i>	<i>L. fermentum</i>	OmpA	Surface	Stability	Animal	97
<i>Clostridium tetani</i>	<i>L. casei</i>	TTFC	Surface, intracell., secreted	Serum IgG	Human	119
<i>Clostridium tetani</i>	<i>L. plantarum</i>	TTFC	Intracell.	Serum IgG, mucosal IgA	Human	120
<i>Clostridium tetani</i>	<i>L. plantarum</i>	TTFC	Intracell.	Serum IgG	Human	121
<i>Clostridium tetani</i>	<i>L. johnsonii</i>	TTFC	Surface	Serum IgG, mucosal IgA	Human	122
<i>Clostridium tetani</i>	<i>L. plantarum</i>	TTFC	Intracell., secreted, surface	Serum IgG, mucosal IgA	Human	123
<i>Clostridium tetani</i>	<i>L. plantarum</i>	TTFC	Intracell.	Serum IgG, mucosal IgA, T cell response, challenge	Human	124
<i>Clostridium tetani</i>	<i>L. plantarum</i> , <i>L. casei</i>	TTFC	Intracell., surface	Serum IgG, mucosal IgA, T cell response	Human	125
<i>Chlamydia trachomatis</i>	<i>L. plantarum</i> , <i>L. fermentum</i>	VD4	Surface	Stability	Human	126
<i>Chlamydia trachomatis</i>	<i>L. plantarum</i>	Hirep2	Surface	Serum IgG, serum IgA, mucosal IgA, IFN- γ	Human	90
<i>Escherichia coli</i> (EHEC O157:H7)	<i>L. acidophilus</i>	EspA, Tir	Secreted	Serum IgG, mucosal sIgA, IFN- γ , IL-4, IL-10, challenge	Human	127
<i>Escherichia coli</i> (EPEC)	<i>L. casei</i>	β -Intimin	Unknown	Serum IgG, mucosal IgM, challenge	Human	77
<i>Escherichia coli</i> (ETEC)	<i>L. casei</i>	K88	Unknown	Serum IgG, mucosal sIgA, challenge	Human	128
<i>Escherichia coli</i> (ETEC)	<i>L. casei</i>	FaeG	Secreted	Stability	Human	129
<i>Escherichia coli</i> (ETEC)	<i>L. casei</i>	FP	Secreted	Stability	Human	129
<i>Escherichia coli</i> (ETEC)	<i>L. casei</i>	F1	Surface	Serum IgG, mucosal IgA, challenge	Swine, ruminants, human	75
<i>Escherichia coli</i> (ETEC)	<i>L. casei</i>	K88, K99	Surface	Serum IgG, mucosal IgA, T cell response	Swine, ruminants, human	74
<i>Escherichia coli</i> (ETEC)	<i>L. casei</i>	K99	Surface	Serum IgG, mucosal IgA	Swine, ruminants, human	73
<i>Escherichia coli</i> (ETEC)	<i>L. casei</i>	F41	Surface	Serum IgG, mucosal IgA, T cell response	Swine, ruminants, human	72
<i>Escherichia coli</i> (ETEC)	<i>L. reuteri</i>	ST, LT(B)	Secreted	Serum IgG, mucosal IgA, challenge protection	Swine, ruminants, human	76
<i>Escherichia coli</i> (ETEC)	<i>L. acidophilus</i>	K99	Surface	<i>In vitro</i> inhibition of pathogen adhesion	Swine, ruminants, human	130

(Continued on next page)

TABLE 2 (Continued)

Pathogen	<i>Lactobacillus</i> species	Antigen(s) expressed	Expression	Result(s)	Intended host(s)	Reference
<i>Escherichia coli</i> (EPEC)	<i>L. plantarum</i>	Fimbrial adhesin (FaeG)	Unknown	Serum IgG, intestinal IgA, challenge	Swine, ruminant, human	131
<i>Escherichia coli</i> (UPEC)	<i>L. reuteri</i>	PapG	Surface	Stability	Human	132
<i>Helicobacter pylori</i>	<i>L. acidophilus</i>	Hp0410	Unknown	Serum IgG, mucosal IgA, challenge	Human	85
<i>Helicobacter pylori</i>	<i>L. acidophilus</i>	Hp0410	Surface	Stability	Human	133
<i>Helicobacter pylori</i>	<i>L. plantarum</i>	UreB	Unknown	Serum IgG, serum IgA, challenge	Human	134
<i>Mycobacterium avium</i> (MAP)	<i>L. salivarius</i>	MMP	Surface	Stability	Ruminant	135
<i>Mycobacterium avium</i> (MAP)	<i>L. salivarius</i>	ptD	Intracell.	Stability	Ruminant	136
<i>Mycobacterium tuberculosis</i>	<i>L. plantarum</i>	Ag85B, ESAT-6	Surface	Mucosal IgA, T cell response	Human	137
<i>Salmonella enterica</i> (SE)	<i>L. casei</i>	FliC, SipC	Surface	Serum IgG, T cell response	Human, animal	138
<i>Salmonella enterica</i> (SE)	<i>L. casei</i>	FliC	Surface	Challenge	Human	139
<i>Streptococcus mutans</i>	<i>L. zeae</i>	scFv	Surface, secreted	Challenge	Human	140
<i>Streptococcus pneumoniae</i>	<i>L. casei</i>	PspC	Surface, intracell.	Mucosal IgA, challenge	Human	141
<i>Streptococcus pneumoniae</i>	<i>L. casei</i>	PspA, PspC	Surface	Serum IgG, mucosal IgA	Human	81
<i>Streptococcus pneumoniae</i>	<i>L. casei</i>	PspA	Surface	Serum IgG, challenge	Human	80
<i>Streptococcus pneumoniae</i>	<i>L. casei</i> , <i>L. plantarum</i> , <i>L. helveticus</i>	PspA	Surface	Serum IgG, mucosal IgA, challenge	Human	79
<i>Streptococcus pneumoniae</i>	<i>L. casei</i>	PsaA, PspA' 1, PspA' 3	Intracell., secreted	Stability	Human	142
<i>Streptococcus pyogenes</i>	<i>L. gasseri</i>	CRR6	Unknown	Serum IgG, mucosal IgA, challenge	Human	143
<i>Streptococcus pyogenes</i>	<i>L. sake</i> , <i>L. fermentum</i>	M6	Secreted, surface	Stability	Human	144
<i>V. cholerae</i>	<i>L. casei</i> , <i>L. reuteri</i>	CTB	Intracell., secreted	Serum IgG	Human	145
<i>Vibrio parahaemolyticus</i>	<i>L. rhamnosus</i>	MAM-7	Unknown	MAM-7 expression (reduced <i>Lactobacillus</i> ability to inhibit pathogen)	Human	146
<i>Vibrio parahaemolyticus</i>	<i>L. rhamnosus</i>	MAM-7	Unknown	Stability	Human	146
<i>Yersinia pestis</i>	<i>L. plantarum</i>	LcrV	Surface	Serum IgG, mucosal IgA, T cell response	Human	84
<i>Yersinia pseudotuberculosis</i>	<i>L. plantarum</i>	D1-D5, D4-D5	Surface	Stability	Human	147

^aFHA, filamentous hemagglutinin adhesin; BoNT, clostridial botulinum neurotoxin; TTFC, tetanus toxin fragment C; FP, fusion protein; MMP, mucous membrane pemphigoid; intracell., intracellular; Neutr. Ab, neutralizing antibody.

infect via the gastrointestinal tract in livestock and the respiratory tract in birds and humans, causing devastating economic losses and dangerous morbidities in the young, old, and immunocompromised (38). The first coronavirus addressed using lactobacilli was transmissible gastroenteritis coronavirus (TGEV), which affects swine, particularly piglets. Several spike protein epitopes have been targeted (S, 6D), resulting in induction of serum IgG and mucosal IgA in mice (39, 40). More recently, the muramyl dipeptide (MDP) protein was targeted, utilizing tuftsin as an adjuvant, and the results showed improved antibody and T cell responses in BALB/c mice (41). The only human coronavirus addressed was SARS-CoV, with induction of serum IgG and mucosal IgA against spike proteins (SA, SB) observed in C57BL/6 mice (42). Porcine epidemic diarrhea virus (PEDV) is another coronavirus that primarily affects piglets, resulting in large economic losses (43). In a thorough set of experiments, Liu et al. showed that, by targeting both the spike protein (S1) and nucleocapsid (N) via surface expression (rather than via

secretion), levels of anti-S1 and anti-N antibodies were significantly increased, even in atypically studied secretions such as ophthalmic and nasal secretions (44). Interestingly, they observed a synergy against the spike protein, but not against the nucleocapsid, in mice vaccinated against both proteins.

To improve the immune response against TGEV's core neutralizing epitope (COE), Ge et al. fused the COE with *E. coli* enterotoxin B (LTB), with results which showed some statistical significance, particularly with respect to splenocyte IFN- γ and IL-4 secretion (45). In perhaps the most directly useful study, Hou et al. observed the increased presence of anti-nucleocapsid antibodies in the milk and colostrum of nursing sows, correlating with increased anti-N serum IgG levels in suckling piglets (46). A recent set of experiments by Jiang et al. delved deeper into the immune response generated by *L. casei*, highlighted by strong mucosa-dependent protection from infection, stimulation of the IL-17 pathway, and an imbalance between the Th1 and Th2 responses, as indicated by variations in numbers of CD4⁺ T cells containing either intracellular IFN- γ or IL-4 (47). Interestingly, some *Lactobacillus* species have been shown to downregulate IL-17 responses (48), but this simply points to the delicate balance that Th17 cells must strike between pathogen-stimulated inflammation and the potential damage of errant autoimmune inflammation (49). It is clear that homeostasis with respect to inflammation, immunity, lactobacilli, and Th17 cells is a complex subject and is dependent on a number of factors, including host genetics, pathogen, *Lactobacillus* strain, and adjuvants.

Rotavirus. Diarrheal disease is the second leading cause of death in children under the age of 5 worldwide, with rotavirus responsible for 40% of hospitalizations due to diarrheal illness (50). It is estimated that rotavirus killed approximately 215,000 children in 2013. The World Health Organization recommends inclusion of a rotavirus vaccine in all global vaccination protocols, and there are currently two modified live vaccines licensed worldwide (51). The global implementation is ongoing, but in countries where data are available, vaccination has resulted in a 33% reduction in hospitalization due to rotavirus morbidities. Unfortunately, both vaccines have limited (50% to 60%) efficacy in developing countries and are associated with a low-level risk of intussusception (52). A recombinant *Lactobacillus*-based vaccine could address the need for a subunit rotavirus vaccine that provides the benefits of a probiotic and the appropriate safety profile for use in neonates and infants. Two main avenues of lactobacillus-based rotavirus protection have been attempted in mice. The first avenue used typical oral vaccination with *L. casei*, inducing mucosal IgA and neutralizing serum IgG against porcine *Rotavirus* major protective antigen (PA) VP4 in mice (53). The second used antibody fragments to confer protection. Álvarez et al. expressed a protective anti-rotavirus llama antibody fragment on the surface of *L. rhamnosus*, protecting against diarrhea in a mouse pup model (54). Another group adapted the use of anti-rotavirus hyperimmune bovine colostrum (HBC) in the same model system, expressing an anti-HBC protein from *Streptococcus*, which binds HBC antibodies, thus conferring protection when orally dosed (55).

Fish-related viruses. Aquaculture is an important food supply paradigm, and with it comes the typical pathogen problems that large-scale animal farms encounter. Vaccination against fish pathogens can be performed by intraperitoneal administration (which can be cost-prohibitive), by immersion, or orally via feed, with the latter two options suffering from a lack of vaccine persistence in water and from the particularly strong mucosal tolerance observed in fish. For a comprehensive summary of vaccination attempts in fish, see the excellent review by Embregts and Forlenza (56). *Lactobacillus* vaccine vectors can provide an effective and easily administered system for pisciculture. The first set of studies targeted infectious pancreatic necrosis virus (IPNV), a birnavirus that afflicts rainbow trout. Direct oral administration with *L. casei* expressing portions of viral capsid generated significant serum IgM and afforded challenge protection in two studies by the same group (57, 58). Two viruses that primarily affect carp, *Cyprinid herpesvirus 3* (Koi herpesvirus [KHV]) and *Rhabdovirus carpio* (spring

viremia of carp virus [SVCV]), have also been studied. The two antigens (KHV ORF81 and SVCV glycoprotein) were expressed together in *L. plantarum* and dosed orally in carp and koi. The resulting serum IgM and challenge survival data were promising, particularly for a vaccine that offers dual protection (59). Further *Lactobacillus* studies must be conducted, looking in particular at cellular mucosal immunity in fish, as well as at the potential for multiple pathogens to be addressed with a single modified *Lactobacillus* vaccine.

Other viruses. In addition to the categories already addressed, a large and diverse number of viruses have been targeted using *Lactobacillus* vector systems. A few are highlighted here, with the rest detailed in Table 1. Classical swine fever virus (CSFV), a flavivirus affecting pigs, has been tested in rabbits, mice, and pigs, with all tests resulting in production of serum and mucosal antibodies (60, 61). Importantly, addition of thymosin α -1, a T cell-stimulating peptide, was able to increase levels of IgG, IgA, IFN- γ , IL-2, and tumor necrosis factor alpha (TNF- α) in pigs (62). *Porcine parvovirus* has been studied in BALB/c mice and pigs, with excellent IgG and IgA responses, as well as challenge protection and virus neutralization (60, 63, 64). A recent study observed strong protective immune responses in chickens against *Newcastle disease virus*, a paramyxovirus primarily afflicting poultry, which were improved by the addition of DC-pep, which not only boosted mucosal and serum antibody levels but also increased levels of T helper cells in the spleen and peripheral blood versus the results seen with bacteria without DC-pep (65). Foot-and-mouth disease virus, a *Picornavirus* afflicting cloven-hooved animals, was investigated in a comprehensive dosing study that assessed anticapsid immune responses resulting from administration of recombinant *L. acidophilus* via the intramuscular, intraperitoneal, intranasal, or oral route. Of note, this vaccine strategy utilized the bacteria as a delivery vehicle for a capsid-expressing DNA vaccine plasmid, in contrast to utilization of expression of heterologous proteins by the bacteria. The resulting antibody responses were thus much higher via intramuscular and intraperitoneal administration than via mucosal delivery (66). As the ease of use and awareness of *Lactobacillus* expression systems and their abilities to induce excellent mucosal and systemic immune responses increase, the number and variety of pathogens addressed will likely increase in the future.

BACTERIA

***Bacillus anthracis*.** Though infections are relatively rare, the prevalence of natural *Bacillus anthracis* in soil and its potential as a bioterrorist agent gives antianthrax vaccines some priority. Protective antigen (PA), the only antigen used in *Lactobacillus* vaccinations, is well studied and has been tested in other vaccine systems with various degrees of success (67). One of the earliest proof-of-concept *Lactobacillus* experiments involved dosing BALB/c mice with *L. casei* either orally or intranasally. That early study showed that the antibody responses against heterologous protein exceeded the antibody responses against the bacteria itself (68). Ten years later, Mohamadzadeh et al. combined an *L. acidophilus* or *L. gasseri* strain with DC-pep, resulting in neutralizing antibodies and challenge survival in A/J mice (69, 70). That same group later observed colonic DC activation, Th17 and regulatory T cell (Treg) upregulation, and upregulation of pattern recognition receptor genes with a single vaccine dose (71).

***Escherichia coli*.** Enteric *Escherichia coli* bacteria are a major cause of diarrheal morbidity and mortality, particularly for children in developing countries. The most common antigens targeted for *E. coli* vaccination are fimbrial proteins, which are bacterial adhesins that aid in host cell binding. Most experiments mentioned here, except one, have targeted enterotoxigenic *E. coli* (ETEC). A prolific group from China utilized several fimbrial protein antigens (F41, K99, K88) over several years and in several models (BALB/c, C57BL/6, BALB/c pups), all using *L. casei*. Among their many findings, an increase in levels of several subclasses of serum IgG (IgG1, IgG2a, IgG2b) followed oral dosing, along with increased IL-4 levels and a lesser increase of IFN- γ levels measured by CD4⁺ T cell enzyme-linked immunosorbent spot (ELISPOT) assays. Intestinal and bronchiolar IgA levels were increased, and challenge with standard ETEC

resulted in protection of >80% of mice challenged with a lethal dose (72). The studies were repeated using intranasal dosing, which resulted in decreased intestinal IgA levels but increased bronchiolar IgA levels compared to oral delivery (73). Dosing in C57BL/6 mice induced similar IgG and IgA responses, as well as T cell proliferation and challenge protection (74). Challenge protection was conferred to mouse pups born to orally or intranasally immunized dams (75). Wu and Chung targeted two enterotoxins (ST and LT-B), rather than fimbrial proteins, with a secreted green fluorescent protein (GFP)/enterotoxin fusion protein. Similar increases in IgG and IgA levels were observed as well as challenge protection in a patent mouse gut assay (76). Ferreira et al. were the only group to target enteropathogenic *E. coli* (EPEC) and attempted the only sublingual dosing regimen. Experiments using *L. casei* expressing a portion of bacterial β -intimin (a cell surface protein that aids in attachment to the host cell) resulted in serum IgG and fecal IgA responses, though, interestingly, oral dosing did not generate an IgG response. Splenocytes also secreted elevated levels of IL-6 and IFN- γ , though only the results from the sublingual vaccination were reported (77). While Ferreira et al. performed their studies in C57BL/6 mice, they used C3H/HePas mice as their challenge model, due to that strain's susceptibility to *Citrobacter rodentium*, a commonly used strain that shares some pathology with EPEC (78). Ferreira et al. observed an increase in survival time, though animals eventually succumbed to disease.

***Streptococcus pneumoniae*.** Most *Lactobacillus* experiments involving *Streptococcus pneumoniae* have been performed by the Oliveira laboratory and have focused on pneumococcal surface proteins (either PspA or PspC), with immunity studies conducted in C57BL/6 mice. Early work noted significant increases in bronchiolar IgA but not IgG levels following intranasal administration, with some variations due to bacterial strain differences (79). Strategies to increase antigen expression resulted in increased IgG levels (IgA levels were not measured), with enhancement of multiple IgG subsets (IgG1, IgG2a, IgG2b, IgG3). Challenge survival was improved compared to that seen with controls inoculated with saline solution alone, but no differences from the results seen with animals immunized with bacteria expressing the empty vector plasmid were observed (80). Further experiments identified a propensity for responses involving IgG1 versus IgG2a, which, along with increased IFN- γ levels and low levels of IL-5, indicated Th1 polarization. The levels of IL-17 secretion and neutrophil recruitment in the lungs varied by route of administration, adding to the idea of the importance of the manner in which vaccines are administered and not just of their expression of antigens (81). A final set of experiments failed to induce significant levels of IgA prior to challenge, but the researchers noted that challenge with *S. pneumoniae* did induce a significant IgA response, which correlated with reduced bacterial loads.

Other bacteria. Very few of the large number of pathogenic bacterial species have been targeted with lactobacilli, and such studies have been reported in only a few research publications. A few are highlighted here, with the rest addressed in Table 2. *Borrelia burgdorferi*, the causative agent of Lyme disease, was targeted with an *L. plantarum* system, resulting in 100% protection following a *B. burgdorferi*-infected tick challenge (82). Those authors also identified what has become an interesting theme with lactobacillus vaccinations, i.e., that of dual Th1 and Th2 induction. *In vitro* work with human cells resulted in Th1 and Th2 cytokine responses, and oral administration in C3H-HeJ mice resulted in induction of both IgG1 (Th2) and IgG2a (Th1) (83). The same authors also targeted *Yersinia pestis* with *L. plantarum*, observing once again both inflammatory (TNF- α , IL-12, IFN- γ , and IL-6) and anti-inflammatory (IL-10) cytokines, indicating stimulation of both Th1 and Th2 responses (84). Importantly, however, as with the previous experiment, those were human *ex vivo* cytokine studies whose results were not confirmed *in vivo*. A vaccine targeting *Helicobacter pylori*, a common cause of stomach ulcers, would be extremely beneficial. By targeting *H. pylori* adhesin Hp0410 with an *L. acidophilus* strain, Hongying et al. generated anti-adhesion serum IgG and intestinal IgA that reduced bacterial

load and gastric inflammation following challenge (85). Antibodies against the ϵ -toxoid of *Clostridium perfringens* were identified in BALB/c mice following oral *L. casei* administration, and though the statistical significance of the antibody levels was unclear, the animals survived challenge (86).

CONCLUSIONS

In order to combat most pathogens at their main point of entry, next-generation vaccines must establish protective mucosal immunity (87). Lactic acid bacteria, particularly species of genus *Lactobacillus*, have shown great promise as mucosal vectors that are capable of driving both systemic and mucosal responses, especially in combination with adjuvants. The number of studies involving lactobacilli has steadily increased over the last 20 years, and as data accumulate, key concepts regarding the immune responses that these vectors elicit have emerged. Interestingly, coinduction of Th1 and Th2 cytokines points to the complexity of T cell subsets in the mucosa. A growing number of studies have suggested that T cell effector plasticity in the mucosa, especially in the gut, is the norm and that the gut must strike a balance between tolerance and inflammation (88). This appears to be one major factor arising from these *Lactobacillus* studies, since evidence of Th17 inflammation, as well as of Treg-based tolerance, points to a complex T cell response. In terms of mucosal vaccination, this reiterates the importance of maintaining a balanced and well-characterized approach to immunogenicity. More work must be done to identify the contributing immune pathways within the mucosa, especially the routes of bacterial uptake into immune inductive sites (M cells, DCs).

There are several major takeaways as development of LAB vaccine platforms continues. While the safety of LAB is an important strength, enhancing protective immunogenicity is a key challenge. Several studies have explored strategies to express adjuvants such as cytokines, pathogen-associated molecular patterns, toxins, and targeting molecules for M cells and DCs. A mechanistic understanding of each of these strategies is necessary to design the right combination of immunogens and adjuvants that will result in protection. The route of administration, while typically oral for LAB, can have an effect on the type of response elicited due to differences in mucosal inductive sites. The intrinsic differences between strains of lactobacilli, as well as the location of antigen expression (surface display, intracellular, secreted), can alter the resulting immune response, and the strains must therefore be properly selected for specific antigens (89). Boosting is also clearly a component of successful vaccination, and there is evidence that heterologous prime-boost strategies may improve, or at least alter, the resulting immune response (90). As always, the model system must be taken into consideration, especially in light of new evidence for mucosal immune differences between the two most common mouse models (BALB/c and C57BL/6) (91). On the basis of their safety and efficacy, as well as their overall cost, *Lactobacillus* vaccine vectors hold great promise as mucosal vaccines. It is anticipated that the use of clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 analysis will allow a more sophisticated approach to engineering vaccine candidates (92). Ultimately, it is critical for one of these candidates to successfully navigate the regulatory gauntlet and demonstrate efficacy in a target population.

REFERENCES

- Rosales-Mendoza S, Angulo C, Meza B. 2016. Food-grade organisms as vaccine biofactories and oral delivery vehicles. *Trends Biotechnol* 34: 124–136. <https://doi.org/10.1016/j.tibtech.2015.11.007>.
- Wells JM, Mercenier A. 2008. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. *Nat Rev Microbiol* 6:349–362. <https://doi.org/10.1038/nrmicro1840>.
- Lee SF, Hulbah M, Halperin SA. 2016. Development of a gene delivery system in *Streptococcus gordonii* using thymidylate synthase as a selection marker. *J Microbiol Methods* 125:43–48. <https://doi.org/10.1016/j.mimet.2016.04.003>.
- Pontes DS, de Azevedo MS, Chatel JM, Langella P, Azevedo V, Miyoshi A. 2011. *Lactococcus lactis* as a live vector: heterologous protein production and DNA delivery systems. *Protein Expr Purif* 79:165–175. <https://doi.org/10.1016/j.pep.2011.06.005>.
- Wyszyńska A, Kobierecka P, Bardowski J, Jagusztyn-Krynicka EK. 2015. Lactic acid bacteria—20 years exploring their potential as live vectors for mucosal vaccination. *Appl Microbiol Biotechnol* 99:2967–2977. <https://doi.org/10.1007/s00253-015-6498-0>.
- Bermúdez-Humarán LG, Kharrat P, Chatel JM, Langella P. 2011. *Lactococci* and *lactobacilli* as mucosal delivery vectors for therapeutic pro-

- teins and DNA vaccines. *Microb Cell Fact* 10(Suppl 1):S4. <https://doi.org/10.1186/1475-2859-10-S1-S4>.
7. Lin IY, Van TT, Smooker PM. 2015. Live-attenuated bacterial vectors: tools for vaccine and therapeutic agent delivery. *Vaccines* 3:940–972. <https://doi.org/10.3390/vaccines3040940>.
 8. Song JA, Kim HJ, Hong SK, Lee DH, Lee SW, Song CS, Kim KT, Choi IS, Lee JB, Park SY. 2016. Oral intake of *Lactobacillus rhamnosus* M21 enhances the survival rate of mice lethally infected with influenza virus. *J Microbiol Immunol Infect* 49:16–23. <https://doi.org/10.1016/j.jmii.2014.07.011>.
 9. Beerepoot M, Geerlings S. 2016. Non-antibiotic prophylaxis for urinary tract infections. *Pathogens* 5:E36. <https://doi.org/10.3390/pathogens5020036>.
 10. National Center for HIV/AIDS, STD and TB Prevention. 2016. CDC fact sheet: new HIV infections in the United States. CDC, Atlanta, GA.
 11. Gilbert PB, Berger JO, Stablein D, Becker S, Essex M, Hammer SM, Kim JH, Degruittola VG. 2011. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. *J Infect Dis* 203:969–975. <https://doi.org/10.1093/infdis/jiq152>.
 12. Kajikawa A, Zhang L, Long J, Nordone S, Stoeker L, LaVoy A, Bumgardner S, Klaenhammer T, Dean G. 2012. Construction and immunological evaluation of dual cell surface display of HIV-1 gag and *Salmonella enterica* serovar Typhimurium FliC in *Lactobacillus acidophilus* for vaccine delivery. *Clin Vaccine Immunol* 19:1374–1381. <https://doi.org/10.1128/CI.00049-12>.
 13. Kajikawa A, Zhang L, LaVoy A, Bumgardner S, Klaenhammer TR, Dean GA. 2015. Mucosal immunogenicity of genetically modified *Lactobacillus acidophilus* expressing an HIV-1 epitope within the surface layer protein. *PLoS One* 10:e0141713. <https://doi.org/10.1371/journal.pone.0141713>.
 14. Kuczowska K, Mathiesen G, Eijnsink VG, Øynebråten I. 2015. *Lactobacillus plantarum* displaying CCL3 chemokine in fusion with HIV-1 Gag derived antigen causes increased recruitment of T cells. *Microb Cell Fact* 14:169. <https://doi.org/10.1186/s12934-015-0360-z>.
 15. Notario-Pérez F, Ruiz-Caro R, Veiga-Ochoa MD. 2017. Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes. *Drug Des Dev Ther* 11:1767–1787. <https://doi.org/10.2147/DDDT.S133170>.
 16. Lagenaur LA, Sanders-Beer BE, Brichacek B, Pal R, Liu X, Liu Y, Yu R, Venzon D, Lee PP, Hamer DH. 2011. Prevention of vaginal SHIV transmission in macaques by a live recombinant *Lactobacillus*. *Mucosal Immunol* 4:648–657. <https://doi.org/10.1038/mi.2011.30>.
 17. Brichacek B, Lagenaur LA, Lee PP, Venzon D, Hamer DH. 2013. In vivo evaluation of safety and toxicity of a *Lactobacillus jensenii* producing modified cyanovirin-N in a rhesus macaque vaginal challenge model. *PLoS One* 8:e78817. <https://doi.org/10.1371/journal.pone.0078817>.
 18. Lagenaur LA, Swedek I, Lee PP, Parks TP. 2015. Robust vaginal colonization of macaques with a novel vaginally disintegrating tablet containing a live biotherapeutic product to prevent HIV infection in women. *PLoS One* 10:e0122730. <https://doi.org/10.1371/journal.pone.0122730>.
 19. Marcolab A, Liu X, Zhang W, Dimitrov AS, Jia L, Lee PP, Fouts TR, Parks TP, Lagenaur LA. 2016. Expression of HIV-1 neutralizing antibody fragments using human vaginal *Lactobacillus*. *AIDS Res Hum Retroviruses* 32:964–971. <https://doi.org/10.1089/AID.2015.0378>.
 20. Lowy DR, Schiller JT. 2012. Reducing HPV-associated cancer globally. *Cancer Prev Res (Phila)* 5:18–23. <https://doi.org/10.1158/1940-6207.CAPR-11-0542>.
 21. Basu P, Banerjee D, Singh P, Bhattacharya C, Biswas J. 2013. Efficacy and safety of human papillomavirus vaccine for primary prevention of cervical cancer: a review of evidence from phase III trials and national programs. *S Asian J Cancer* 2:187–192. <https://doi.org/10.4103/2278-330X.119877>.
 22. Keating KM, Brewer NT, Gottlieb SL, Liddon N, Ludema C, Smith JS. 2008. Potential barriers to HPV vaccine provision among medical practices in an area with high rates of cervical cancer. *J Adolesc Health* 43:S61–S67. <https://doi.org/10.1016/j.jadohealth.2008.06.015>.
 23. Aires KA, Cianciarullo AM, Carneiro SM, Villa LL, Boccardo E, Pérez-Martínez G, Pérez-Arellano I, Oliveira ML, Ho PL. 2006. Production of human papillomavirus type 16 L1 virus-like particles by recombinant *Lactobacillus casei* cells. *Appl Environ Microbiol* 72:745–752. <https://doi.org/10.1128/AEM.72.1.745-752.2006>.
 24. Yim EK, Park JS. 2005. The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. *Cancer Res Treat* 37:319–324. <https://doi.org/10.4143/crt.2005.37.6.319>.
 25. Poo H, Pyo HM, Lee TY, Yoon SW, Lee JS, Kim CJ, Sung MH, Lee SH. 2006. Oral administration of human papillomavirus type 16 E7 displayed on *Lactobacillus casei* induces E7-specific antitumor effects in C57/BL6 mice. *Int J Cancer* 119:1702–1709. <https://doi.org/10.1002/ijc.22035>.
 26. Lee TY, Kim YH, Lee KS, Kim JK, Lee IH, Yang JM, Sung MH, Park JS, Poo H. 2010. Human papillomavirus type 16 E6-specific antitumor immunity is induced by oral administration of HPV16 E6-expressing *Lactobacillus casei* in C57BL/6 mice. *Cancer Immunol Immunother* 59:1727–1737. <https://doi.org/10.1007/s00262-010-0903-4>.
 27. Yoon SW, Lee TY, Kim SJ, Lee IH, Sung MH, Park JS, Poo H. 2012. Oral administration of HPV-16 L2 displayed on *Lactobacillus casei* induces systematic and mucosal cross-neutralizing effects in Balb/c mice. *Vaccine* 30:3286–3294. <https://doi.org/10.1016/j.vaccine.2012.03.009>.
 28. Adachi K, Kawana K, Yokoyama T, Fujii T, Tomio A, Miura S, Tomio K, Kojima S, Oda K, Sewaki T, Yasugi T, Kozuma S, Taketani Y. 2010. Oral immunization with a *Lactobacillus casei* vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7. *Vaccine* 28:2810–2817. <https://doi.org/10.1016/j.vaccine.2010.02.005>.
 29. Ribelles P, Benbouziane B, Langella P, Suárez JE, Bermúdez-Humarán LG. 2013. Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface. *Appl Microbiol Biotechnol* 97:1231–1239. <https://doi.org/10.1007/s00253-012-4575-1>.
 30. Cortes-Perez NG, Lefèvre F, Corthier G, Adel-Patient K, Langella P, Bermúdez-Humarán LG. 2007. Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria. *Vaccine* 25:6581–6588. <https://doi.org/10.1016/j.vaccine.2007.06.062>.
 31. Kawana K, Adachi K, Kojima S, Taguchi A, Tomio K, Yamashita A, Nishida H, Nagasaka K, Arimoto T, Yokoyama T, Wada-Hiraike O, Oda K, Sewaki T, Osuga Y, Fujii T. 2014. Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients. *Vaccine* 32:6233–6239. <https://doi.org/10.1016/j.vaccine.2014.09.020>.
 32. Shi SH, Yang WT, Yang GL, Cong YL, Huang HB, Wang Q, Cai RP, Hu LP, Hu JT, Zhou JY, Wang CF, Li Y. 2014. Immunoprotection against influenza virus H9N2 by the oral administration of recombinant *Lactobacillus plantarum* NC8 expressing hemagglutinin in BALB/c mice. *Virology* 464–465:166–176. <https://doi.org/10.1016/j.virol.2014.07.011>.
 33. Shi SH, Yang WT, Yang GL, Zhang XK, Liu YY, Zhang LJ, Ye LP, Hu JT, Xing X, Qi C, Li Y, Wang CF. 2016. *Lactobacillus plantarum* vaccine vector expressing hemagglutinin provides protection against H9N2 challenge infection. *Virus Res* 211:46–57. <https://doi.org/10.1016/j.virusres.2015.09.005>.
 34. Wang Z, Yu Q, Gao J, Yang Q. 2012. Mucosal and systemic immune responses induced by recombinant *Lactobacillus* spp. expressing the hemagglutinin of the avian influenza virus H5N1. *Clin Vaccine Immunol* 19:174–179. <https://doi.org/10.1128/CI.05618-11>.
 35. Wang Z, Yu Q, Fu J, Liang J, Yang Q. 2013. Immune responses of chickens inoculated with recombinant *Lactobacillus* expressing the haemagglutinin of the avian influenza virus. *J Appl Microbiol* 115:1269–1277. <https://doi.org/10.1111/jam.12325>.
 36. Chowdhury MY, Li R, Kim JH, Park ME, Kim TH, Pathinayake P, Weerasingha P, Song MK, Son HY, Hong SP, Sung MH, Lee JS, Kim CJ. 2014. Mucosal vaccination with recombinant *Lactobacillus casei*-displayed CTA1-conjugated consensus matrix protein-2 (sM2) induces broad protection against divergent influenza subtypes in BALB/c mice. *PLoS One* 9:e94051. <https://doi.org/10.1371/journal.pone.0094051>.
 37. Li R, Chowdhury MY, Kim JH, Kim TH, Pathinayake P, Koo WS, Park ME, Yoon JE, Roh JB, Hong SP, Sung MH, Lee JS, Kim CJ. 2015. Mucosally administered *Lactobacillus* surface-displayed influenza antigens (sM2 and HA2) with cholera toxin subunit A1 (CTA1) induce broadly protective immune responses against divergent influenza subtypes. *Vet Microbiol* 179:250–263. <https://doi.org/10.1016/j.vetmic.2015.07.020>.
 38. Fehr AR, Perlman S. 2015. Coronaviruses: an overview of their replication and pathogenesis. *Methods Mol Biol* 1282:1–23. https://doi.org/10.1007/978-1-4939-2438-7_1.
 39. Ho PS, Kwang J, Lee YK. 2005. Intra-gastric administration of *Lactobacillus casei* expressing transmissible gastroenteritis coronavirus spike

- glycoprotein induced specific antibody production. *Vaccine* 23: 1335–1342. <https://doi.org/10.1016/j.vaccine.2004.09.015>.
40. Di-Qiu L, Xin-Yuan Q, Jun-Wei G, Li-Jie T, Yan-Ping J, Yi-Jing L. 2011. Construction and characterization of *Lactobacillus pentosus* expressing the D antigenic site of the spike protein of Transmissible gastroenteritis virus. *Can J Microbiol* 57:392–397. <https://doi.org/10.1139/w11-027>.
 41. Jiang X, Yu M, Qiao X, Liu M, Tang L, Jiang Y, Cui W, Li Y. 2014. Up-regulation of MDP and tuftsin gene expression in Th1 and Th17 cells as an adjuvant for an oral *Lactobacillus casei* vaccine against anti-transmissible gastroenteritis virus. *Appl Microbiol Biotechnol* 98: 8301–8312. <https://doi.org/10.1007/s00253-014-5893-2>.
 42. Lee JS, Poo H, Han DP, Hong SP, Kim K, Cho MW, Kim E, Sung MH, Kim CJ. 2006. Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on *Lactobacillus casei* induces neutralizing antibodies in mice. *J Virol* 80:4079–4087. <https://doi.org/10.1128/JVI.80.8.4079-4087.2006>.
 43. Song D, Park B. 2012. Porcine epidemic diarrhoea virus: a comprehensive review of molecular epidemiology, diagnosis, and vaccines. *Virus Genes* 44:167–175. <https://doi.org/10.1007/s11262-012-0713-1>.
 44. Liu DQ, Ge JW, Qiao XY, Jiang YP, Liu SM, Li YJ. 2012. High-level mucosal and systemic immune responses induced by oral administration with *Lactobacillus*-expressed porcine epidemic diarrhoea virus (PEDV) S1 region combined with *Lactobacillus*-expressed N protein. *Appl Microbiol Biotechnol* 93:2437–2446. <https://doi.org/10.1007/s00253-011-3734-0>.
 45. Ge JW, Liu DQ, Li YJ. 2012. Construction of recombinant *lactobacilli* expressing the core neutralizing epitope (COE) of porcine epidemic diarrhoea virus and a fusion protein consisting of COE and *Escherichia coli* heat-labile enterotoxin B, and comparison of the immune responses by orogastric immunization. *Can J Microbiol* 58:1258–1267. <https://doi.org/10.1139/w2012-098>.
 46. Hou XL, Yu LY, Liu J, Wang GH. 2007. Surface-displayed porcine epidemic diarrhoea viral (PEDV) antigens on lactic acid bacteria. *Vaccine* 26:24–31. <https://doi.org/10.1016/j.vaccine.2007.10.065>.
 47. Jiang X, Hou X, Tang L, Jiang Y, Ma G, Li Y. 2016. A phase trial of the oral *Lactobacillus casei* vaccine polarizes Th2 cell immunity against transmissible gastroenteritis coronavirus infection. *Appl Microbiol Biotechnol* 100:7457–7469. <https://doi.org/10.1007/s00253-016-7424-9>.
 48. Tanabe S. 2013. The effect of probiotics and gut microbiota on Th17 cells. *Int Rev Immunol* 32:511–525. <https://doi.org/10.3109/08830185.2013.839665>.
 49. Chewing JH, Weaver CT. 2014. Development and survival of Th17 cells within the intestines: the influence of microbiome- and diet-derived signals. *J Immunol* 193:4769–4777. <https://doi.org/10.4049/jimmunol.1401835>.
 50. Wardlaw T, Salama P, Brocklehurst C, Chopra M, Mason E. 2010. Diarrhoea: why children are still dying and what can be done. *Lancet* 375:870–872. [https://doi.org/10.1016/S0140-6736\(09\)61798-0](https://doi.org/10.1016/S0140-6736(09)61798-0).
 51. Anonymous. 2013. Rotavirus vaccines WHO position paper: January 2013—recommendations. *Vaccine* 31:6170–6171. <https://doi.org/10.1016/j.vaccine.2013.05.037>.
 52. O’Ryan M. 2017. Rotavirus vaccines: a story of success with challenges ahead. *F1000Res* 6:1517. <https://doi.org/10.12688/f1000research.11912.1>.
 53. Qiao X, Li G, Wang X, Li X, Liu M, Li Y. 2009. Recombinant porcine rotavirus VP4 and VP4-LTB expressed in *Lactobacillus casei* induced mucosal and systemic antibody responses in mice. *BMC Microbiol* 9:249. <https://doi.org/10.1186/1471-2180-9-249>.
 54. Álvarez B, Krogh-Andersen K, Tellgren-Roth C, Martínez N, Günaydin G, Lin Y, Martín MC, Álvarez MA, Hammarström L, Marcotte H. 2015. An exopolysaccharide-deficient mutant of *Lactobacillus rhamnosus* GG efficiently displays a protective llama antibody fragment against rotavirus on its surface. *Appl Environ Microbiol* 81:5784–5793. <https://doi.org/10.1128/AEM.00945-15>.
 55. Günaydin G, Zhang R, Hammarström L, Marcotte H. 2014. Engineered *Lactobacillus rhamnosus* GG expressing IgG-binding domains of protein G: capture of hyperimmune bovine colostrum antibodies and protection against diarrhoea in a mouse pup rotavirus infection model. *Vaccine* 32:470–477. <https://doi.org/10.1016/j.vaccine.2013.11.057>.
 56. Embregts CW, Forlenza M. 2016. Oral vaccination of fish: lessons from humans and veterinary species. *Dev Comp Immunol* 64:118–137. <https://doi.org/10.1016/j.dci.2016.03.024>.
 57. Min L, Li-Li Z, Jun-Wei G, Xin-Yuan Q, Yi-Jing L, Di-Qiu L. 2012. Immunogenicity of *Lactobacillus*-expressing VP2 and VP3 of the infectious pancreatic necrosis virus (IPNV) in rainbow trout. *Fish Shellfish Immunol* 32:196–203. <https://doi.org/10.1016/j.fsi.2011.11.015>.
 58. Zhao LL, Liu M, Ge JW, Qiao XY, Li YJ, Liu DQ. 2012. Expression of infectious pancreatic necrosis virus (IPNV) VP2-VP3 fusion protein in *Lactobacillus casei* and immunogenicity in rainbow trouts. *Vaccine* 30:1823–1829. <https://doi.org/10.1016/j.vaccine.2011.12.132>.
 59. Cui LC, Guan XT, Liu ZM, Tian CY, Xu YG. 2015. Recombinant *lactobacillus* expressing G protein of spring viremia of carp virus (SVCV) combined with ORF81 protein of koi herpesvirus (KHV): a promising way to induce protective immunity against SVCV and KHV infection in cyprinid fish via oral vaccination. *Vaccine* 33:3092–3099. <https://doi.org/10.1016/j.vaccine.2015.05.002>.
 60. Xu Y, Cui L, Tian C, Zhang G, Huo G, Tang L, Li Y. 2011. Immunogenicity of recombinant classic swine fever virus CD8(+) T lymphocyte epitope and porcine parvovirus VP2 antigen coexpressed by *Lactobacillus casei* in swine via oral vaccination. *Clin Vaccine Immunol* 18:1979–1986. <https://doi.org/10.1128/CLVI.05204-11>.
 61. Xu YG, Cui LC, Ge JW, Zhao LL, Li YJ. 2007. The oral immune efficacy of recombinant *Lactobacillus casei* expressing CSFV E290 peptide and it elicited specific CTL response. *Sheng Wu Gong Cheng Xue Bao* 23: 930–934. (In Chinese).
 62. Xu YG, Guan XT, Liu ZM, Tian CY, Cui LC. 2015. Immunogenicity in swine of orally administered recombinant *Lactobacillus plantarum* expressing classical swine fever virus E2 protein in conjunction with thymosin alpha-1 as an adjuvant. *Appl Environ Microbiol* 81: 3745–3752. <https://doi.org/10.1128/AEM.00127-15>.
 63. Xu Y, Li Y. 2007. Induction of immune responses in mice after intragastric administration of *Lactobacillus casei* producing porcine parvovirus VP2 protein. *Appl Environ Microbiol* 73:7041–7047. <https://doi.org/10.1128/AEM.00436-07>.
 64. Yigang XU, Yijing LI. 2008. Construction of recombinant *Lactobacillus casei* efficiently surface displayed and secreted porcine parvovirus VP2 protein and comparison of the immune responses induced by oral immunization. *Immunology* 124:68–75. <https://doi.org/10.1111/j.1365-2567.2007.02738.x>.
 65. Jiang Y, Hu J, Guo Y, Yang W, Ye L, Shi C, Liu Y, Yang G, Wang C. 2015. Construction and immunological evaluation of recombinant *Lactobacillus plantarum* expressing HN of Newcastle disease virus and DC-targeting peptide fusion protein. *J Biotechnol* 216:82–89. <https://doi.org/10.1016/j.jbiotec.2015.09.033>.
 66. Li YG, Tian FL, Gao FS, Tang XS, Xia C. 2007. Immune responses generated by *Lactobacillus* as a carrier in DNA immunization against foot-and-mouth disease virus. *Vaccine* 25:902–911. <https://doi.org/10.1016/j.vaccine.2006.09.034>.
 67. McComb RC, Martchenko M. 2016. Neutralizing antibody and functional mapping of *Bacillus anthracis* protective antigen—the first step toward a rationally designed anthrax vaccine. *Vaccine* 34:13–19. <https://doi.org/10.1016/j.vaccine.2015.11.025>.
 68. Zegers ND, Kluter E, van Der Stap H, van Dura E, van Dalen P, Shaw M, Baillie L. 1999. Expression of the protective antigen of *Bacillus anthracis* by *Lactobacillus casei*: towards the development of an oral vaccine against anthrax. *J Appl Microbiol* 87:309–314. <https://doi.org/10.1046/j.1365-2672.1999.00900.x>.
 69. Mohamadzadeh M, Duong T, Sandwick SJ, Hoover T, Klaenhammer TR. 2009. Dendritic cell targeting of *Bacillus anthracis* protective antigen expressed by *Lactobacillus acidophilus* protects mice from lethal challenge. *Proc Natl Acad Sci U S A* 106:4331–4336. <https://doi.org/10.1073/pnas.0900029106>.
 70. Mohamadzadeh M, Durmaz E, Zadeh M, Pakanati KC, Gramarossa M, Cohran V, Klaenhammer TR. 2010. Targeted expression of anthrax protective antigen by *Lactobacillus gasserii* as an anthrax vaccine. *Future Microbiol* 5:1289–1296. <https://doi.org/10.2217/fmb.10.78>.
 71. Kathania M, Zadeh M, Lightfoot YL, Roman RM, Sahay B, Abbott JR, Mohamadzadeh M. 2013. Colonic immune stimulation by targeted oral vaccine. *PLoS One* 8:e55143. <https://doi.org/10.1371/journal.pone.0055143>.
 72. Liu JK, Hou XL, Wei CH, Yu LY, He XJ, Wang GH, Lee JS, Kim CJ. 2009. Induction of immune responses in mice after oral immunization with recombinant *Lactobacillus casei* strains expressing enterotoxigenic *Escherichia coli* F41 fimbrial protein. *Appl Environ Microbiol* 75: 4491–4497. <https://doi.org/10.1128/AEM.02672-08>.
 73. Wei CH, Liu JK, Hou XL, Yu LY, Lee JS, Kim CJ. 2010. Immunogenicity and protective efficacy of orally or intranasally administered recombinant *Lactobacillus casei* expressing ETEC K99. *Vaccine* 28:4113–4118. <https://doi.org/10.1016/j.vaccine.2009.05.088>.
 74. Wen LJ, Hou XL, Wang GH, Yu LY, Wei XM, Liu JK, Liu Q, Wei CH. 2012.

- Immunization with recombinant *Lactobacillus casei* strains producing K99, K88 fimbrial protein protects mice against enterotoxigenic *Escherichia coli*. *Vaccine* 30:3339–3349. <https://doi.org/10.1016/j.vaccine.2011.08.036>.
75. Liu JK, Wei CH, Hou XL, Yu LY. 2014. Passive protection of mice pups through oral or intranasal immunization of dams with recombinant *Lactobacillus casei* vaccine against ETEC F41. *Res Vet Sci* 96:283–287. <https://doi.org/10.1016/j.rvsc.2014.01.010>.
 76. Wu CM, Chung TC. 2007. Mice protected by oral immunization with *Lactobacillus reuteri* secreting fusion protein of *Escherichia coli* enterotoxin subunit protein. *FEMS Immunol Med Microbiol* 50:354–365. <https://doi.org/10.1111/j.1574-695X.2007.00255.x>.
 77. Ferreira PC, da Silva JB, Piazza RM, Eckmann L, Ho PL, Oliveira ML. 2011. Immunization of mice with *Lactobacillus casei* expressing a beta-intimin fragment reduces intestinal colonization by *Citrobacter rodentium*. *Clin Vaccine Immunol* 18:1823–1833. <https://doi.org/10.1128/CI.05262-11>.
 78. Collins JW, Keeney KM, Crepin VF, Rathinam VA, Fitzgerald KA, Finlay BB, Frankel G. 2014. *Citrobacter rodentium*: infection, inflammation and the microbiota. *Nat Rev Microbiol* 12:612–623. <https://doi.org/10.1038/nrmicro3315>.
 79. Oliveira ML, Arêas AP, Campos IB, Monedero V, Perez-Martínez G, Miyaji EN, Leite LC, Aires KA, Lee Ho P. 2006. Induction of systemic and mucosal immune response and decrease in *Streptococcus pneumoniae* colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A. *Microbes Infect* 8:1016–1024. <https://doi.org/10.1016/j.micinf.2005.10.020>.
 80. Campos IB, Darrieux M, Ferreira DM, Miyaji EN, Silva DA, Arêas AP, Aires KA, Leite LC, Ho PL, Oliveira ML. 2008. Nasal immunization of mice with *Lactobacillus casei* expressing the pneumococcal surface protein A: induction of antibodies, complement deposition and partial protection against *Streptococcus pneumoniae* challenge. *Microbes Infect* 10:481–488. <https://doi.org/10.1016/j.micinf.2008.01.007>.
 81. Ferreira DM, Darrieux M, Silva DA, Leite LC, Ferreira JM, Jr, Ho PL, Miyaji EN, Oliveira ML. 2009. Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice. *Clin Vaccine Immunol* 16:636–645. <https://doi.org/10.1128/CI.00395-08>.
 82. del Rio B, Dattwyler RJ, Aroso M, Neves V, Meirelles L, Seegers JF, Gomes-Solecki M. 2008. Oral immunization with recombinant *Lactobacillus plantarum* induces a protective immune response in mice with Lyme disease. *Clin Vaccine Immunol* 15:1429–1435. <https://doi.org/10.1128/CI.00169-08>.
 83. del Rio B, Seegers JF, Gomes-Solecki M. 2010. Immune response to *Lactobacillus plantarum* expressing *Borrelia burgdorferi* OspA is modulated by the lipid modification of the antigen. *PLoS One* 5:e11199. <https://doi.org/10.1371/journal.pone.0011199>.
 84. del Rio B, Fuente JL, Neves V, Dattwyler R, Seegers JF, Gomes-Solecki M. 2010. Platform technology to deliver prophylactic molecules orally: an example using the class A select agent *Yersinia pestis*. *Vaccine* 28:6714–6722. <https://doi.org/10.1016/j.vaccine.2010.07.084>.
 85. Hongying F, Xianbo W, Fang Y, Yang B, Beiguo L. 2014. Oral immunization with recombinant *Lactobacillus acidophilus* expressing the adhesin Hp0410 of *Helicobacter pylori* induces mucosal and systemic immune responses. *Clin Vaccine Immunol* 21:126–132. <https://doi.org/10.1128/CI.00434-13>.
 86. Alimolaei M, Golchin M, Daneshvar H. 2016. Oral immunization of mice against *Clostridium perfringens* epsilon toxin with a *Lactobacillus casei* vector vaccine expressing epsilon toxin. *Infect Genet Evol* 40:282–287. <https://doi.org/10.1016/j.meegid.2016.03.020>.
 87. Boyaka PN. 2017. Inducing mucosal IgA: a challenge for vaccine adjuvants and delivery systems. *J Immunol* 199:9–16. <https://doi.org/10.4049/jimmunol.1601775>.
 88. Bhaumik S, Basu R. 2017. Cellular and molecular dynamics of Th17 differentiation and its developmental plasticity in the intestinal immune response. *Front Immunol* 8:254. <https://doi.org/10.3389/fimmu.2017.00254>.
 89. Bron PA, Tomita S, Mercenier A, Kleerebezem M. 2013. Cell surface-associated compounds of probiotic lactobacilli sustain the strain-specificity dogma. *Curr Opin Microbiol* 16:262–269. <https://doi.org/10.1016/j.mib.2013.06.001>.
 90. Kuczowska K, Myrbråten I, Øverland L, Eijsink VGH, Follmann F, Mathiesen G, Dietrich J. 2017. *Lactobacillus plantarum* producing a *Chlamydia trachomatis* antigen induces a specific IgA response after mucosal booster immunization. *PLoS One* 12:e0176401. <https://doi.org/10.1371/journal.pone.0176401>.
 91. Fransén F, Zagato E, Mazzini E, Fosso B, Manzari C, El Aïdy S, Chiavelli A, D'Erchia AM, Sethi MK, Pabst O, Marzano M, Moretti S, Romani L, Penna G, Pesole G, Rescigno M. 2015. BALB/c and C57BL/6 mice differ in polyreactive IgA abundance, which impacts the generation of antigen-specific IgA and microbiota diversity. *Immunity* 43:527–540. <https://doi.org/10.1016/j.immuni.2015.08.011>.
 92. Hidalgo-Cantabrana C, O'Flaherty S, Barrangou R. 2017. CRISPR-based engineering of next-generation lactic acid bacteria. *Curr Opin Microbiol* 37:79–87. <https://doi.org/10.1016/j.mib.2017.05.015>.
 93. Moeini H, Rahim RA, Omar AR, Shafee N, Yusoff K. 2011. *Lactobacillus acidophilus* as a live vehicle for oral immunization against chicken anemia virus. *Appl Microbiol Biotechnol* 90:77–88. <https://doi.org/10.1007/s00253-010-3050-0>.
 94. Xu YG, Cui LC, Ge JW, Zhao LL, Li YJ. 2007. Co-expression of CSFV T cell epitope E290 peptide and PPV VP2 protein in *Lactobacillus casei* and determination of specific antibodies in immunized mice. *Wei Sheng Wu Xue Bao* 47:667–672.
 95. Pouwels PH, Leer RJ, Boersma WJ. 1996. The potential of *Lactobacillus* as a carrier for oral immunization: development and preliminary characterization of vector systems for targeted delivery of antigens. *J Biotechnol* 44:183–192. [https://doi.org/10.1016/0168-1656\(95\)00140-9](https://doi.org/10.1016/0168-1656(95)00140-9).
 96. Liu YY, Yang WT, Shi SH, Li YJ, Zhao L, Shi CW, Zhou FY, Jiang YL, Hu JT, Gu W, Yang GL, Wang CF. 2017. Immunogenicity of recombinant *Lactobacillus plantarum* NC8 expressing goose parvovirus VP2 gene in BALB/c mice. *J Vet Sci* 18:159–167. <https://doi.org/10.4142/jvs.2017.18.2.159>.
 97. Turner MS, Giffard PM. 1999. Expression of *Chlamydia psittaci*- and human immunodeficiency virus-derived antigens on the cell surface of *Lactobacillus fermentum* BR11 as fusions to bspA. *Infect Immun* 67:5486–5489.
 98. Taguchi A, Kawana K, Yokoyama T, Adachi K, Yamashita A, Tomio K, Kojima S, Oda K, Fujii T, Kozuma S. 2012. Adjuvant effect of Japanese herbal medicines on the mucosal type 1 immune responses to human papillomavirus (HPV) E7 in mice immunized orally with *Lactobacillus*-based therapeutic HPV vaccine in a synergistic manner. *Vaccine* 30:5368–5372. <https://doi.org/10.1016/j.vaccine.2012.06.027>.
 99. Sewaki T. 2009. Generation of mucosal vaccine utilizing *Lactobacillus* display system. *Yakugaku Zasshi* 129:1327–1332. (In Japanese.) <https://doi.org/10.1248/yakushi.129.1327>.
 100. Cortes-Perez NG, Azevedo V, Alcocer-González JM, Rodríguez-Padilla C, Tamez-Guerra RS, Corthier G, Gruss A, Langella P, Bermúdez-Humarán LG. 2005. Cell-surface display of E7 antigen from human papillomavirus type-16 in *Lactococcus lactis* and in *Lactobacillus plantarum* using a new cell-wall anchor from lactobacilli. *J Drug Target* 13:89–98. <https://doi.org/10.1080/10611860400024219>.
 101. Lin H, Hou S, Wang S, Wang Y, Luanl Y, Hou X. 2014. Immunogenicity of recombinant *Lactobacillus casei* expressing VP2 protein of infectious bursal disease virus in chickens. *Sheng Wu Gong Cheng Xue Bao* 30:1679–1690. (In Chinese.)
 102. Ma BC, Yang X, Wang HN, Cao HP, Xu PW, Ding MD, Liu H. 2016. Characterization of a new *Lactobacillus salivarius* strain engineered to express IBV multi-epitope antigens by chromosomal integration. *Biosci Biotechnol Biochem* 80:574–583. <https://doi.org/10.1080/09168451.2015.1101330>.
 103. Suebwongsa N, Lulitanond V, Mayo B, Yotpanya P, Panya M. 2016. Development of an *Escherichia coli*-*Lactobacillus casei* shuttle vector for heterologous protein expression in *Lactobacillus casei*. *Springerplus* 5:169. <https://doi.org/10.1186/s40064-016-1760-1>.
 104. Suebwongsa N, Panya M, Namwat W, Sookprasert S, Redruello B, Mayo B, Alvarez MA, Lulitanond V. 2013. Cloning and expression of a codon-optimized gene encoding the influenza A virus nucleocapsid protein in *Lactobacillus casei*. *Int Microbiol* 16:93–101. <https://doi.org/10.2436/20.1501.01.184>.
 105. Yang WT, Yang GL, Wang Q, Huang HB, Jiang YL, Shi CW, Wang JZ, Huang KY, Jin YB, Wang CF. 2017. Protective efficacy of Fc targeting conserved influenza virus M2e antigen expressed by *Lactobacillus plantarum*. *Antiviral Res* 138:9–21. <https://doi.org/10.1016/j.antiviral.2016.11.025>.
 106. Yang WT, Yang GL, Shi SH, Liu YY, Huang HB, Jiang YL, Wang JZ, Shi CW, Jing YB, Wang CF. 2017. Protection of chickens against H9N2 avian influenza virus challenge with recombinant *Lactobacillus plantarum*

- expressing conserved antigens. *Appl Microbiol Biotechnol* 101: 4593–4603. <https://doi.org/10.1007/s00253-017-8230-8>.
107. Yang WT, Shi SH, Yang GL, Jiang YL, Zhao L, Li Y, Wang CF. 2016. Cross-protective efficacy of dendritic cells targeting conserved influenza virus antigen expressed by *Lactobacillus plantarum*. *Sci Rep* 6:39665. <https://doi.org/10.1038/srep39665>.
 108. Tan TS, Syed Hassan S, Yap WB. 2017. Expression of surface-bound nonstructural 1 (NS1) protein of influenza virus A H5N1 on *Lactobacillus casei* strain C1. *Lett Appl Microbiol* 64:446–451. <https://doi.org/10.1111/lam.12738>.
 109. Martín MC, Fernández M, Martín-Alonso JM, Parra F, Boga JA, Alvarez MA. 2004. Nisin-controlled expression of Norwalk virus VP60 protein in *Lactobacillus casei*. *FEMS Microbiol Lett* 237:385–391. <https://doi.org/10.1111/j.1574-6968.2004.tb09721.x>.
 110. Li X, Xia C, Li Y. 2009. Induced expression of alpha-toxin gene of *Clostridium perfringens* in recombinant *Lactobacillus casei* and their immunoprotective in mice. *Wei Sheng Wu Xue Bao* 49:1115–1120. (In Chinese).
 111. Hu J, Wang C. 2008. Expression and immunogenicity analysis of recombinant plasmid pW425et-Vp7 of porcine rotavirus A in *Lactobacillus*. *Wei Sheng Wu Xue Bao* 48:1514–1519. (In Chinese).
 112. Yin JY, Guo CQ, Wang Z, Yu ML, Gao S, Bukhari SM, Tang LJ, Xu YG, Li YJ. 2016. Directed chromosomal integration and expression of porcine rotavirus outer capsid protein VP4 in *Lactobacillus casei* ATCC393. *Appl Microbiol Biotechnol* 100:9593–9604. <https://doi.org/10.1007/s00253-016-7779-y>.
 113. Günaydin G, Alvarez B, Lin Y, Hammarström L, Marcotte H. 2014. Co-expression of anti-rotavirus proteins (llama VHH antibody fragments) in *Lactobacillus*: development and functionality of vectors containing two expression cassettes in tandem. *PLoS One* 9:e96409. <https://doi.org/10.1371/journal.pone.0096409>.
 114. O'Flaherty S, Klaenhammer TR. 2016. Multivalent chromosomal expression of the *Clostridium botulinum* serotype A neurotoxin heavy-chain antigen and the *Bacillus anthracis* protective antigen in *Lactobacillus acidophilus*. *Appl Environ Microbiol* 82:6091–6101. <https://doi.org/10.1128/AEM.01533-16>.
 115. Colombi D, Oliveira ML, Campos IB, Monedero V, Pérez-Martínez G, Ho PL. 2006. Haemagglutination induced by *Bordetella pertussis* filamentous haemagglutinin adhesin (FHA) is inhibited by antibodies produced against FHA(430-873) fragment expressed in *Lactobacillus casei*. *Curr Microbiol* 53:462–466. <https://doi.org/10.1007/s00284-005-0388-0>.
 116. Zhao L, Guo Z, Liu J, Wang Z, Wang R, Li Y, Wang L, Xu Y, Tang L, Qiao X. 2017. Recombinant *Lactobacillus casei* expressing *Clostridium perfringens* toxoids alpha, beta2, epsilon and beta1 gives protection against *Clostridium perfringens* in rabbits. *Vaccine* 35:4010–4021. <https://doi.org/10.1016/j.vaccine.2017.05.076>.
 117. Alimolaei M, Golchin M, Ezatkhah M. 2017. Orally administered recombinant *Lactobacillus casei* vector vaccine expressing beta-toxoid of *Clostridium perfringens* that induced protective immunity responses. *Res Vet Sci* 115:332–339. <https://doi.org/10.1016/j.rvsc.2017.06.018>.
 118. Alimolaei M, Golchin M, Abshenas J, Ezatkhah M, Bafti MS. 2017. A recombinant probiotic, *Lactobacillus casei*, expressing the *Clostridium perfringens* alpha-toxoid, as an orally vaccine candidate against gas gangrene and necrotic enteritis. *Probiotics Antimicrob Proteins*. <https://doi.org/10.1007/s12602-017-9276-8>.
 119. Maassen CB, Laman JD, den Bak-Glashouwer MJ, Tielen FJ, van Holten-Neelen JC, Hoogteijling L, Antonissen C, Leer RJ, Pouwels PH, Boersma WJ, Shaw DM. 1999. Instruments for oral disease-intervention strategies: recombinant *Lactobacillus casei* expressing tetanus toxin fragment C for vaccination or myelin proteins for oral tolerance induction in multiple sclerosis. *Vaccine* 17:2117–2128. [https://doi.org/10.1016/S0264-410X\(99\)00010-9](https://doi.org/10.1016/S0264-410X(99)00010-9).
 120. Grangette C, Müller-Alouf H, Hols P, Goudercourt D, Delcour J, Turneer M, Mercenier A. 2004. Enhanced mucosal delivery of antigen with cell wall mutants of lactic acid bacteria. *Infect Immun* 72:2731–2737. <https://doi.org/10.1128/IAI.72.5.2731-2737.2004>.
 121. Grangette C, Müller-Alouf H, Geoffroy M, Goudercourt D, Turneer M, Mercenier A. 2002. Protection against tetanus toxin after intragastric administration of two recombinant lactic acid bacteria: impact of strain viability and in vivo persistence. *Vaccine* 20:3304–3309. [https://doi.org/10.1016/S0264-410X\(02\)00301-8](https://doi.org/10.1016/S0264-410X(02)00301-8).
 122. Scheppler L, Vogel M, Zuercher AW, Zuercher M, Germond JE, Miescher SM, Stadler BM. 2002. Recombinant *Lactobacillus johnsonii* as a mucosal vaccine delivery vehicle. *Vaccine* 20:2913–2920. [https://doi.org/10.1016/S0264-410X\(02\)00229-3](https://doi.org/10.1016/S0264-410X(02)00229-3).
 123. Reveanu N, Geoffroy MC, Loch C, Chagnaud P, Mercenier A. 2002. Comparison of the immune responses induced by local immunizations with recombinant *Lactobacillus plantarum* producing tetanus toxin fragment C in different cellular locations. *Vaccine* 20: 1769–1777. [https://doi.org/10.1016/S0264-410X\(02\)00027-0](https://doi.org/10.1016/S0264-410X(02)00027-0).
 124. Grangette C, Müller-Alouf H, Goudercourt D, Geoffroy MC, Turneer M, Mercenier A. 2001. Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant *Lactobacillus plantarum*. *Infect Immun* 69:1547–1553. <https://doi.org/10.1128/IAI.69.3.1547-1553.2001>.
 125. Shaw DM, Gaerthé B, Leer RJ, Van Der Stap JG, Smittenaar C, Heijne Den Bak-Glashouwer M, Thole JE, Tielen FJ, Pouwels PH, Havenith CE. 2000. Engineering the microflora to vaccinate the mucosa: serum immunoglobulin G responses and activated draining cervical lymph nodes following mucosal application of tetanus toxin fragment C-expressing lactobacilli. *Immunology* 100:510–518. <https://doi.org/10.1046/j.1365-2567.2000.00069.x>.
 126. Rush C, Hafner L, Timms P. 1997. Protein A as a fusion partner for the expression of heterologous proteins in *Lactobacillus*. *Appl Microbiol Biotechnol* 47:537–542. <https://doi.org/10.1007/s002530050969>.
 127. Lin R, Zhang Y, Long B, Li Y, Wu Y, Duan S, Zhu B, Wu X, Fan H. 2017. Oral immunization with recombinant *Lactobacillus acidophilus* expressing espA-Tir-M confers protection against enterohemorrhagic *Escherichia coli* O157:H7 challenge in mice. *Front Microbiol* 8:417. <https://doi.org/10.3389/fmicb.2017.00417>.
 128. Yu M, Qi R, Chen C, Yin J, Ma S, Shi W, Wu Y, Ge J, Jiang Y, Tang L, Xu Y, Li Y. 2017. Immunogenicity of recombinant *Lactobacillus casei*-expressing F4 (K88) fimbrial adhesin FaeG in conjunction with a heat-labile enterotoxin A (LTAK63) and heat-labile enterotoxin B (LTB) of enterotoxigenic *Escherichia coli* as an oral adjuvant in mice. *J Appl Microbiol* 122:506–515. <https://doi.org/10.1111/jam.13352>.
 129. Lu WW, Wang T, Wang Y, Xin M, Kong J. 2016. A food-grade fimbrial adhesin FaeG expression system in *Lactococcus lactis* and *Lactobacillus casei*. *Can J Microbiol* 62:241–248. <https://doi.org/10.1139/cjm-2015-0596>.
 130. Chu H, Kang S, Ha S, Cho K, Park SM, Han KH, Kang SK, Lee H, Han SH, Yun CH, Choi Y. 2005. *Lactobacillus acidophilus* expressing recombinant K99 adhesive fimbriae has an inhibitory effect on adhesion of enterotoxigenic *Escherichia coli*. *Microbiol Immunol* 49:941–948. <https://doi.org/10.1111/j.1348-0421.2005.tb03687.x>.
 131. Yang G, Jiang Y, Tong P, Li C, Yang W, Hu J, Ye L, Gu W, Shi C, Shan B, Wang C. 2017. Alleviation of enterotoxigenic *Escherichia coli* challenge by recombinant *Lactobacillus plantarum* expressing a FaeG and DC-targeting peptide fusion protein. *Benef Microbes* 8:379–391. <https://doi.org/10.3920/BM2016.0116>.
 132. Ashrafi F, Fallah Mehrabadi J, Siadat SD, Aghasadeghi MR. 2015. Expression and purification of the uropathogenic *Escherichia coli* PapG protein and its surface absorption on *Lactobacillus reuteri*: implications for surface display system vaccines. *Jundishapur J Microbiol* 8:e25595. <https://doi.org/10.5812/jjm.25595>.
 133. Zhu LF, Long BG, Luo J, Jiang R, Fang HY. 2010. Construction of a recombinant *Lactobacillus acidophilus* expressing high levels of *Helicobacter pylori* adhesin Hp0410. *Nan Fang Yi Ke Da Xue Xue Bao* 30:334–337. (In Chinese).
 134. Corthésy B, Boris S, Isler P, Grangette C, Mercenier A. 2005. Oral immunization of mice with lactic acid bacteria producing *Helicobacter pylori* urease B subunit partially protects against challenge with *Helicobacter felis*. *J Infect Dis* 192:1441–1449. <https://doi.org/10.1086/444425>.
 135. Johnston CD, Bannantine JP, Govender R, Endersen L, Pletzer D, Weingart H, Coffey A, O'Mahony J, Sleator RD. 2014. Enhanced expression of codon optimized *Mycobacterium avium* subsp. *paratuberculosis* antigens in *Lactobacillus salivarius*. *Front Cell Infect Microbiol* 4:120. <https://doi.org/10.3389/fcimb.2014.00120>.
 136. Johnston C, Douarre PE, Soulimane T, Pletzer D, Weingart H, MacSharry J, Coffey A, Sleator RD, O'Mahony J. 2013. Codon optimisation to improve expression of a *Mycobacterium avium* ssp. *paratuberculosis*-specific membrane-associated antigen by *Lactobacillus salivarius*. *Pathog Dis* 68:27–38. <https://doi.org/10.1111/2049-632X.12040>.
 137. Kuczkowska K, Kleiveland CR, Minic R, Moen LF, Øverland L, Tjåland R, Carlsen H, Lea T, Mathiesen G, Eijsink VG. 2017. Immunogenic properties of *Lactobacillus plantarum* producing surface-displayed *Mycobac-*

- terium tuberculosis antigens. *Appl Environ Microbiol* 83. <https://doi.org/10.1128/AEM.02782-16>.
138. Kajikawa A, Igimi S. 2010. Innate and acquired immune responses induced by recombinant *Lactobacillus casei* displaying flagellin-fusion antigen on the cell-surface. *Vaccine* 28:3409–3415. <https://doi.org/10.1016/j.vaccine.2010.02.077>.
139. Kajikawa A, Satoh E, Leer RJ, Yamamoto S, Igimi S. 2007. Intra-gastric immunization with recombinant *Lactobacillus casei* expressing flagellar antigen confers antibody-independent protective immunity against *Salmonella enterica* serovar Enteritidis. *Vaccine* 25:3599–3605. <https://doi.org/10.1016/j.vaccine.2007.01.055>.
140. Krüger C, Hu Y, Pan Q, Marcotte H, Hultberg A, Delwar D, van Dalen PJ, Pouwels PH, Leer RJ, Kelly CG, van Dollenweerd C, Ma JK, Hammarström L. 2002. In situ delivery of passive immunity by lactobacilli producing single-chain antibodies. *Nat Biotechnol* 20:702–706. <https://doi.org/10.1038/nbt0702-702>.
141. Hernani MDL, Ferreira PC, Ferreira DM, Miyaji EN, Ho PL, Oliveira ML. 2011. Nasal immunization of mice with *Lactobacillus casei* expressing the pneumococcal surface protein C primes the immune system and decreases pneumococcal nasopharyngeal colonization in mice. *FEMS Immunol Med Microbiol* 62:263–272. <https://doi.org/10.1111/j.1574-695X.2011.00809.x>.
142. Oliveira ML, Monedero V, Miyaji EN, Leite LC, Lee Ho P, Pérez-Martínez G. 2003. Expression of *Streptococcus pneumoniae* antigens, PsaA (pneumococcal surface antigen A) and PspA (pneumococcal surface protein A) by *Lactobacillus casei*. *FEMS Microbiol Lett* 227:25–31. [https://doi.org/10.1016/S0378-1097\(03\)00645-1](https://doi.org/10.1016/S0378-1097(03)00645-1).
143. Mansour NM, Abdelaziz SA. 2016. Oral immunization of mice with engineered *Lactobacillus gasseri* NM713 strain expressing *Streptococcus pyogenes* M6 antigen. *Microbiol Immunol* 60:527–532. <https://doi.org/10.1111/1348-0421.12397>.
144. Piard JC, Hautefort I, Fischetti VA, Ehrlich SD, Fons M, Gruss A. 1997. Cell wall anchoring of the *Streptococcus pyogenes* M6 protein in various lactic acid bacteria. *J Bacteriol* 179:3068–3072. <https://doi.org/10.1128/jb.179.9.3068-3072.1997>.
145. Okuno T, Kashige N, Satho T, Irie K, Hiramatsu Y, Sharmin T, Fukumitsu Y, Uyeda S, Yamada S, Harakuni T, Miyata T, Arakawa T, Imoto M, Toda A, Nakashima Y, Miake F. 2013. Expression and secretion of cholera toxin B subunit in lactobacilli. *Biol Pharm Bull* 36:952–958. <https://doi.org/10.1248/bpb.b12-01021>.
146. Beltran S, Munoz-Bergmann CA, Elola-Lopez A, Quintana J, Segovia C, Trombert AN. 2016. The expression of heterologous MAM-7 in *Lactobacillus rhamnosus* reduces its intrinsic capacity to inhibit colonization of pathogen *Vibrio parahaemolyticus* in vitro. *Biol Res* 49:2. <https://doi.org/10.1186/s40659-015-0064-1>.
147. Fredriksen L, Kleiveland CR, Hult LT, Lea T, Nygaard CS, Eijsink VG, Mathiesen G. 2012. Surface display of N-terminally anchored invasins by *Lactobacillus plantarum* activates NF- κ B in monocytes. *Appl Environ Microbiol* 78:5864–5871. <https://doi.org/10.1128/AEM.01227-12>.